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We investigated an outbreak of unexpectedly severe
histoplasmosis among 14 healthy adventure travelers from
the United States who visited a bat-infested cave in
Nicaragua. Although histoplasmosis has rarely been report-
ed to cause serious illness among travelers, this outbreak
demonstrates that cases may be severe among travelers,
even young, healthy persons. 
H
istoplasmosis is a systemic infection caused by the
dimorphic fungus, Histoplasma capsulatum. Infection
results from inhaling spores, usually through exposure to bat
and bird droppings in barnyards and caves. Although out-
breaks have occurred after visits to bat-infested caves, histo-
plasmosis has not been frequently recognized as travel-relat-
ed and has rarely led to serious illness among young, healthy
travelers. This fungus is endemic in the United States along
the Ohio and Mississippi River valleys and many other parts
of the world, particularly Latin America. Histoplasmosis is
often asymptomatic in endemic settings, but infection can
result in a spectrum of illness, ranging from mild influenza-
like illness to acute pulmonary infection and disseminated
extrapulmonary disease. Immunocompromised persons and
the elderly are at greater risk for disseminated disease (1).
This report describes a recent outbreak of histoplasmosis
among U.S. adventure travelers to Nicaragua that was asso-
ciated with a high attack rate and hospitalizations among
previously healthy travelers. 
The Study
In June 2001, five persons with a febrile respiratory ill-
ness visited a community hospital. The patients were
among 15 persons (age range 19–61 years; median 38
years), residents of four states, who had participated in a
geology-biology community college class trip to
Nicaragua. To determine the cause and describe character-
istics of the outbreak, we interviewed trip participants and
reviewed medical records to collect demographic informa-
tion, clinical history, and activities during the trip. Based
on the partcipant’s exposure to a cave with bats and clini-
cal characteristics suggestive of acute histoplasmosis,
diagnostic testing for histoplasmosis was conducted. 
Acase of acute histoplasmosis was defined as illness in
a person who tested positive by one of the following labo-
ratory tests: serology, urine antigen, histopathology, or cul-
ture. Immunodiffusion and complement- fixation serolog-
ic tests were performed at the Centers for Disease Control
and Prevention (CDC). The immunodiffusion test was con-
sidered positive if an H or M band or both were detected.
A complement-fixation titer to the yeast or mycelial anti-
gens of >1:32 or a fourfold increase in the titer between
acute- and convalescent-phase serum specimens was con-
sidered evidence of acute infection. Acute-phase serum
specimens were obtained 2–3 weeks after exposure.
Convalescent-phase serum specimens were collected
approximately 3 months after exposure. One patient under-
went bronchoalveolar lavage and bronchoscopy, and a
biopsy specimen was obtained. Lung tissue was stained
with hematoxylin and eosin and Gomori methenamine sil-
ver stains. Bronchoalveolar lavage washings were cultured
by conventional methods (2). Identification of the organ-
ism as H. capsulatum was confirmed by GenProbe assay
(GenProbe, San Diego, CA). Urine antigen tests, which
were performed 2 weeks after exposure, are considered
positive if >1 unit is detected (3,4).
The travelers began their trip on May 19 and returned
to the United States on May 30. During their trip, they
explored rock quarries, visited a biological research sta-
tion, swam in freshwater lakes, and were exposed to par-
rots and insects. On May 21, a total of 14 of the 15 travel-
ers entered a small cave that had previously been used as a
silver mine. They remained in the cave for 10 minutes,
during which time they saw several flying bats and bat
guano on the ground. 
The infection rate was 100% among the 14 travelers
who entered the cave, and 12 (86%) were symptomatic. All
14 patients had serologically confirmed infection. Of the
14 patients, 12 (86%) had urine antigen tests (Table). The
only traveler who did not enter the cave tested negative by
serology and urine antigen. 
Of the infected travelers, 8 (57%) were female. The
average incubation period was 11 days (range 10–12 days),
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12 symptomatic persons, 12 (100%) had a fever of 38.9°C
to 40°C, nonproductive cough, myalgias, fever, chills,
night sweats, loss of appetite, and mild headache. Many
had nausea and vomiting (83%), chest pain (58%), and
arthralgias (58%). Six persons had mild to moderate respi-
ratory distress, with oxygen saturation of 88% to 95%. On
physical examination, all the travelers’ lung fields were
clear to auscultation, a feature consistent with histoplas-
mosis infection. The two asymptomatic persons had previ-
ous exposure to bats or caving. Among the symptomatic
persons, we found no differences in severity of symptoms
according to sex, prior exposure to spelunking, residence
in a histoplamosis-endemic area, or activities while in the
mine. 
In accordance with clinical treatment guidelines, physi-
cians decided to treat patients with itraconazole for 6 to 12
weeks; some patients also received steroids (5). No
patients required discontinuation of therapy because of
adverse effects. 
Laboratory studies showed normal complete blood
counts, serum chemistries, and renal function tests. Four
persons had mild to moderate elevation in liver function
tests (alanine aminotransferase, range 55–204; aspartate
aminotransferase, range 48–153; and alkaline phosphatase,
range 95–311). All 12 symptomatic persons had abnormal
chest radiograph results with bilateral nodular infiltrates
(Figure). Two persons had hilar adenopathy, and one had a
small pleural effusion. 
Hematoxylin and eosin–stained sections of the lung tis-
sue from the biopsy showed macrophages and neutrophils
in the interstitium; no granulomatous inflammation was
observed. Gomori methenamine silver stain demonstrated
budding yeasts compatible with H. capsulatum. Culture of
the bronchoalveolar lavage fluid from this patient grew H.
capsulatum after 4 weeks of incubation. 
Conclusions
This report highlights the importance of histoplasmosis
as a potentially serious travel-related illness.
Histoplasmosis is usually considered a mild, self-limited
illness; however, this outbreak of histoplasmosis among
previously healthy travelers was associated with a 100%
infection rate of histoplasmosis and an 86% rate of symp-
tomatic infection in the persons who entered the cave.
Among the symptomatic persons, 50% required hospital-
ization and 83% missed school or work (range: 2 weeks–3
months) as a result of their illness (Table). Because of the
high attack rate and the large percentage of patients with
severe infection, these travelers were likely exposed to
very high concentrations of H. capsulatum spores during
their brief visit inside the cave. 
H. capsulatum exists throughout the world (1,6); how-
ever, nonimmune travelers from areas with a low preva-
lence of histoplasmosis, who engage in high-risk activities
in disease-endemic areas, are at greater risk of acquiring
symptomatic fungal infection. The number of outbreaks of
histoplasmosis, especially among U.S. travelers to Latin
America, has increased. Histoplasmosis has been reported
in groups of travelers who entered caves with bats in Costa
Rica (7; unpub. data, Centers for Disease Control and
Prevention (CDC), Ecuador (8), and Peru (9). In 2001,
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Table: Summary of laboratory testing results and clinical 
outcomes among persons with histoplasmosis 
Characteristic  N (%) 
Diagnostic test result
a   
CF
b and ID
c positive  5 (36) 
CF positive, ID negative  8 (57) 
ID positive, CF negative  1 (7) 
Urine antigen positive
d  7 (58), range 1.2–4.6, median 2.8 
Clinical outcomes
e   
Missed work, school, or both
f  10 (83) 
Treated with itraconazole  9 (75) 
Treated with steroids  7 (58) 
Hospitalized  6 (50) 
Duration of hospitalization  Median 6 d (range 2–11 d) 
Duration of fever  Median 12 d (range 4–26 d) 
Duration of symptoms  Median 42 d (range 16–210 d) 
aAmong 14 persons with histoplasmosis. 
bCF: complement fixation. 
cID: immunodiffusion. 
dUrine antigen tests were performed for 12 persons. 
eAmong the 12 symptomatic persons. 
fFive persons missed 2 weeks–3 months of work, and five persons missed one 
semester of school. 
Figure. Chest radiograph of patient who acquired acute pulmonary
histoplasmosis after visiting a cave in Nicaragua. more than 200 college students became infected with
histoplasmosis during a spring break trip to Acapulco,
Mexico (10,11). Outbreaks and isolated cases of histoplas-
mosis have also been described among non–-U.S. travelers
to Latin America and other areas of the world (12–19).
Clinicians should consider fungal pathogens when
evaluating returning travelers who have a febrile respirato-
ry syndrome. The differential diagnosis of acute febrile
respiratory illness in international adventure travelers is
extensive and includes legionellosis, psittacosis, lep-
tospirosis, schistosomiasis, histoplasmosis, coccid-
ioidomycosis, influenza, parainfluenza, mycoplasma,
dengue, and malaria. 
The timely diagnosis of histoplasmosis in travelers may
be particularly challenging for clinicians evaluating one
sporadic case or a patient involved in an undetected multi-
state outbreak. Antibody response can take 4–6 weeks to
develop, reducing its usefulness in the acute setting and
requiring the collection of a convalescent-phase specimen
for confirmation. Antibodies may also persist for 5 years,
making it difficult to distinguish between prior and recent
infection without obtaining a convalescent-phase speci-
men. The sensitivity of immunodiffusion is 72% to 85%,
while that of complement fixation is 80% to 90% (20,21).
The antigen test can be used for urine, cerebrospinal fluid,
serum, and bronchoalveolar lavage fluid, and results are
available in 24 hours. This test had been used most exten-
sively in AIDS patients; however, it is less sensitive in
nonimmunocompromised persons with acute pulmonary
infection. Sensitivity of the urine antigen test for detection
of acute pulmonary infection ranges from 44% to 75% and
increases when performed early after the onset of symp-
toms (3,4). 
In this outbreak, 80% of the travelers were prescribed
appropriate malaria chemoprophylaxis during a pretravel
assessment. However, most clinicians may not have
thought to counsel them about histoplasmosis risk and pre-
vention. During pretravel visits, clinicians should review
patients’ itineraries for possible fungal exposures and
should counsel them to avoid entering caves, especially
those known to be bat infested. Since travelers may not
know whether their itinerary includes visits to bat-infested
caves, adventure travelers and persons who are at high risk
for severe histoplasmosis infection, such as immunocom-
promised travelers (especially persons with AIDS), should
be counseled to avoid possible exposures, either by avoid-
ing caves or by using special protective masks. The
National Institute for Occupational Safety and Health has
published guidelines for special masks that can be used to
reduce occupational and other exposures (e.g., among spe-
lunkers). Unfortunately, these special masks are bulky and
may be impractical for many travelers. (22). While most
nonimmunocompromised patients with acute pulmonary
histoplasmosis improve without treatment, persons with
hypoxemia, diffuse pulmonary histoplasmosis, or severe
illness requiring hospitalization may benefit from antifun-
gal therapy and, in some cases, corticosteroids (5). 
The contribution of histoplasmosis to infectious disease
illness in travelers is likely underestimated. As adventure
travel becomes increasingly accessible, especially among
persons at high risk, immunocompromised persons, and
the elderly, histoplasmosis and other fungal infections in
travelers may become more common. Enhanced surveil-
lance for histoplasmosis and other fungal infections by
public health officials, combined with heightened aware-
ness by clinicians who are evaluating symptomatic, post-
travel patients, can lead to greater understanding of the
epidemiology of fungal infections among travelers and,
ultimately, to improved prevention measures. 
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